Gynovin

Gynovin is a combined oral contraceptive tablet containing the synthetic estrogen ethinylestradiol and the progestogen gestodene. It is marketed in the European Union and supplied by prescription only. Each tablet delivers a fixed dose of these hormones to provide reliable birth control. The product is classified as an estrogen‑progestogen combination and is taken by mouth according to a weekly regimen, following a 21‑day active, 7‑day placebo schedule.

Gynovin is indicated for the prevention of pregnancy in women of reproductive age who choose an oral hormonal method.

- Regular, once‑daily dosing for 21 consecutive days followed by a 7‑day hormone‑free interval. - Suppression of ovulation through combined estrogen and progestogen action. - Thickening of cervical mucus to impede sperm penetration. - Alteration of the endometrial lining to reduce the likelihood of implantation. - May be used to regulate menstrual cycles when prescribed by a healthcare professional.

Like all combined oral contraceptives, Gynovin may cause side effects that vary in frequency and severity. These effects are generally reversible after discontinuation, but any persistent or severe symptom should be reported to a healthcare provider.

Common: - Nausea or mild stomach upset - Breast tenderness or enlargement - Headache or mild migraine - Spotting or breakthrough bleeding between periods - Weight gain or fluid retention - Mood changes or depression

Serious: - Deep vein thrombosis or pulmonary embolism - Severe hypertension or cardiovascular events - Liver dysfunction indicated by jaundice - Allergic reactions such as rash, itching, or swelling

Before starting Gynovin, certain health conditions and risk factors should be evaluated to ensure safe use of combined hormonal contraception.

- History of thromboembolic disorders, such as deep vein thrombosis or pulmonary embolism. - Current or past cardiovascular disease, including hypertension, stroke, or myocardial infarction. - Smoking, especially in women over 35 years of age. - Known or suspected estrogen‑dependent tumors, such as breast or endometrial cancer. - Liver disease that impairs hormone metabolism. - Unexplained vaginal bleeding of unknown cause.

Gynovin can interact with other medicines, affecting its efficacy or increasing the risk of adverse events.

Avoid: - Strong enzyme inducers such as rifampicin, carbamazepine, phenytoin, and St. John’s wort. - Certain antiviral agents (e.g., efavirenz) that reduce hormone levels. - Protease inhibitors (e.g., ritonavir) that may lower contraceptive effectiveness.

Use with caution: - Anticoagulants (e.g., warfarin) – may require dose adjustment. - Antihypertensives – hormonal changes can affect blood pressure control. - Antidepressants (SSRIs) – may increase risk of mood changes. - Antifungal agents (e.g., ketoconazole) – can increase hormone concentrations.